Pfizer’s sasanlimab combo significantly improves event-free survival in BCG-naïve, high-risk non-muscle invasive bladder cancer: New York Tuesday, April 29, 2025, 14:00 Hrs [IS ...

underscoring the need for BCG maintenance not only as a component of SOC treatment but also in combination with sasanlimab. Early interim analysis for the key secondary overall survival (OS ...

Pfizer Inc. today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus ...

Balfour Capital Group Appoints Yogi Lamba, Strengthening Global Financial Expertise and Analytical Capabilities Balfour Capital Group (BCG), a leading global investment and financial advisory firm, is ...

McKinsey partner Patricio Ibáñez said shoppers are bracing for costs to rise because of tariffs, and a survey led by the ...

Consumer companies like Unilever and Nestlé constantly jostle over pricing to deliver strong top-line figures without ...

Abbott has announced new data from its Volt CE Mark Study that show strong safety and efficacy out to 12 months for patients receiving pulsed field ablation (PFA) therapy with the Volttm PFA System ...